Dong-A Socio Holdings
http://en.donga.co.kr/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Dong-A Socio Holdings
Intas Picks Up Global Rights To Meiji And Dong-A’s Stelara Biosimilar
Japan’s Meiji Seika Pharma and Korea’s Dong-A have struck an exclusive licensing deal with Intas for global rights to the pair’s DMB-3115 proposed ustekinumab biosimilar to Stelara.
AbbVie U-Turns On Dong-A’s MerTK Program After Development Delays
After apparent long delays in development, AbbVie returns rights to Dong-A's MerTK program, with the South Korean pharma yet to determine the fate of the still preclinical stage assets.
Korea Kick-Starts Major Consortium For Next-Gen mRNA Vaccines
South Korea is stepping on the gas to develop its own mRNA COVID-19 vaccine and eventually next generation mRNA platform technology for use in other diseases, to meet its goal of becoming a global vaccine hub.
Biopharma Market Fuels South Korean Growth Engine
South Korea is the tenth largest economy in the world with a population of 51.3 million. Alongside fast growth of the region’s technology-driven economy, its pharma industry has been expanding significantly too.
Company Information
- Industry
- Distributors
- In Vitro Diagnostics
- Medical Devices
- Pharmaceuticals
-
Pharmaceuticals
- Drug Delivery
- OTC, Consumer
-
In Vitro Diagnostics
- Chemistry, Immunoassay
-
Biotechnology
- Gene Therapy, Cell Therapy
- Other Names / Subsidiaries
-
- Dong-A Pharmaceutical Co., Ltd (Dong-A Pharm)
- Dong-A Science Technology Co., Ltd (Dong-A ST)
- Dong-A Socio Group
- JCOM Co. Ltd.
- Mezzion Co. Ltd.